SBIR-STTR Award

Development of a Novel Test for the Early Detection of Dengue Virus Infection
Award last edited on: 12/29/22

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$855,304
Award Phase
2
Solicitation Topic Code
NIAID
Principal Investigator
Emily Ann Stein

Company Information

Sevident Inc

3563 Arden Rd
Hayward, CA 94545
   (510) 780-0131
   info@sevident.com
   www.sevident.com
Location: Single
Congr. District: 15
County: Alameda

Phase I

Contract Number: 1R43AI109869-01
Start Date: 6/15/14    Completed: 5/31/16
Phase I year
2014
Phase I Amount
$577,652
Dengue virus (DENV) is a major public health problem of growing global importance with ~2.5 billion people at risk of infection, 50-100 million cases reported annually and associated costs of $2.1 billion per year in the Western Hemisphere [1,2]. DENV is a mosquito-borne virus and the causative agent of dengue fever, dengue hemorrhagic fever and dengue shock syndrome and is often misdiagnosed due to the non-specific clinical manifestations of this febrile illness [3]. With more than 17 million Americans traveling to endemic areas, dengue infections are now more common in travelers returning to the U.S. than malaria [16]. There is an urgent need for rapid, sensitive and specific point-of-care-compatible DENV diagnostic tools for improved patient care and public health surveillance. In this application, we will explore the discovery that a novel capture technology, CAP-TECH, designed for the specific capture of DENV (ViCAP-DENV) constructed on point-of-care-compatible solid-phase paramagnetic microparticles and their use in a fluorescent immunoassay (FIA) enabled the rapid detection of DENV in minutes. Further, in a comparative study, the sensitivity of fluorescent signal observed by the ViCAP-DENV FIA prototype was comparable to the signal observed by qRT-PCR, but in a fraction of the time and cost. Our overriding hypothesis is that the use of a diagnostic tool, such as ViCAP-DENV FIA, will enable the rapid and sensitive detection of Dengue virus in blood samples, the eventual use of which could improve patient outcomes. Further optimization of ViCAP-DENV and the FIA (Aim 1) and an initial clinical evaluation of ViCAP- DENV FIA performance in a side-by-side comparison study against FDA-approved DENV test methods using de-identified serum samples collected by the Sustainable Sciences Institute and the Nicaraguan Ministry of Health (Aim 2), will provide the foundational work for future product development and field-testing evaluations in Phase II. The success of this application will provide a novel and cost-effective point-of-care-compatible test design for the rapid diagnosis of viral infection from samples within minutes.

Thesaurus Terms:
Acute;Address;American;Area;Base;Binding (Molecular Function);Blood Specimen;Case Study;Centers For Disease Control And Prevention (U.S.);Clinical;Comparative;Comparative Study;Cost;Cost Effective;Cross Reactivity;Culicidae;Data;Dengue;Dengue Hemorrhagic Fever;Dengue Shock Syndrome;Dengue Virus;Design;Detection;Development;Diagnostic;Early Diagnosis;Effectiveness;Enzyme-Linked Immunosorbent Assay;Evaluation/Testing;Fda Approved;Feasibility Studies;Fever;Fluorescence;Future;Goals;Health;Hemorrhagic Shock;Immunoassay;Improved;Infection;Infection Control;Institutes;Kinetics;Lead;Malaria;Methods;Microspheres;Nicaraguan;Noise;Novel;Outcome;Patient Care;Patients;Performance;Phase;Phase 1 Study;Pilot Projects;Plasma;Point Of Care;Population Surveillance;Product Development;Prototype;Ptpn11 Gene;Public Health Medicine (Field);Public Health Relevance;Publishing;Rapid Detection;Rapid Diagnosis;Reagent Testing;Reporter;Reproducibility;Research Clinical Testing;Reverse Transcriptase Polymerase Chain Reaction;Risk;Sampling;Science;Sensitivity And Specificity;Series;Serotyping;Serum;Side;Signal Transduction;Solid;Specificity;Staging;Success;Syndrome;Technology;Test Result;Testing;Time;Tool;Travel;Viral;Viral Detection;Viral Hemorrhagic Fevers;Virus;Virus Diseases;Work;

Phase II

Contract Number: 5R43AI109869-02
Start Date: 6/15/14    Completed: 5/31/16
Phase II year
2015
Phase II Amount
$277,652
Dengue virus (DENV) is a major public health problem of growing global importance with ~2.5 billion people at risk of infection, 50-100 million cases reported annually and associated costs of $2.1 billion per year in the Western Hemisphere [1,2]. DENV is a mosquito-borne virus and the causative agent of dengue fever, dengue hemorrhagic fever and dengue shock syndrome and is often misdiagnosed due to the non-specific clinical manifestations of this febrile illness [3]. With more than 17 million Americans traveling to endemic areas, dengue infections are now more common in travelers returning to the U.S. than malaria [16]. There is an urgent need for rapid, sensitive and specific point-of-care-compatible DENV diagnostic tools for improved patient care and public health surveillance. In this application, we will explore the discovery that a novel capture technology, CAP-TECH, designed for the specific capture of DENV (ViCAP-DENV) constructed on point-of-care-compatible solid-phase paramagnetic microparticles and their use in a fluorescent immunoassay (FIA) enabled the rapid detection of DENV in minutes. Further, in a comparative study, the sensitivity of fluorescent signal observed by the ViCAP-DENV FIA prototype was comparable to the signal observed by qRT-PCR, but in a fraction of the time and cost. Our overriding hypothesis is that the use of a diagnostic tool, such as ViCAP-DENV FIA, will enable the rapid and sensitive detection of Dengue virus in blood samples, the eventual use of which could improve patient outcomes. Further optimization of ViCAP-DENV and the FIA (Aim 1) and an initial clinical evaluation of ViCAP- DENV FIA performance in a side-by-side comparison study against FDA-approved DENV test methods using de-identified serum samples collected by the Sustainable Sciences Institute and the Nicaraguan Ministry of Health (Aim 2), will provide the foundational work for future product development and field-testing evaluations in Phase II. The success of this application will provide a novel and cost-effective point-of-care-compatible test design for the rapid diagnosis of viral infection from samples within minutes.

Public Health Relevance Statement:


Public Health Relevance:
In this application, we will explore the discovery that a novel capture technology, CAP-TECH, designed for the specific capture of Dengue Virus (DENV) signatures, constructed on point-of-care-compatible paramagnetic microparticles and their use in a fluorescent immunoassay enabled the rapid detection of DENV in minutes, the results of which were comparable to qRT-PCR. The success of this application will provide a novel and cost- effective point-of-care-compatible test design for the rapid diagnosis of viral infection fro samples within minutes.

NIH Spending Category:
Biodefense; Bioengineering; Biotechnology; Clinical Research; Emerging Infectious Diseases; Infectious Diseases; Prevention; Rare Diseases; Vector-Borne Diseases

Project Terms:
Acute; Address; American; Area; base; Binding (Molecular Function); Blood specimen; Case Study; Centers for Disease Control and Prevention (U.S.); Clinical; comparative; Comparative Study; cost; cost effective; cross reactivity; Culicidae; Data; Dengue; Dengue Hemorrhagic Fever; Dengue Shock Syndrome; Dengue Virus; design; Detection; Development; Diagnostic; Early Diagnosis; Effectiveness; Enzyme-Linked Immunosorbent Assay; evaluation/testing; FDA approved; Feasibility Studies; Fever; Fluorescence; Future; Goals; Health; Hemorrhagic Shock; Immunoassay; improved; Infection; Infection Control; Institutes; Kinetics; Lead; Malaria; Methods; Microspheres; Nicaraguan; Noise; novel; Outcome; Patient Care; Patients; Performance; Phase; phase 1 study; Pilot Projects; Plasma; point of care; Population Surveillance; product development; prototype; PTPN11 gene; public health medicine (field); Publishing; rapid detection; rapid diagnosis; reagent testing; Reporter; Reproducibility; research clinical testing; Reverse Transcriptase Polymerase Chain Reaction; Risk; Sampling; Science; Sensitivity and Specificity; Series; Serotyping; Serum; Side; Signal Transduction; Solid; Specificity; Staging; success; Syndrome; Technology; Test Result; Testing; Time; tool; Travel; Viral; viral detection; Viral Hemorrhagic Fevers; Virus; Virus Diseases; Work